Liquidia Corporation LQDA

NASDAQ | Biotech | Pulmonary hypertension treatments

General analysis — not personal advice.

Signal

BUY

Sentiment

8/10

Risk

6/10

Operational performance (rapid sequential sales growth, profitability, and rising cash) reduces financing risk and strengthens the bull case.

This picture changes. Follow Liquidia Corporation free — email when the signal or risk changes + a Sunday weekly brief.

Follow Liquidia Corporation free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Price & valuation

Last close

USD 91.03

2026-08-10

1 week

+2.1 %

3 months

+58.1 %

12 months

+277.7 %

From 52w high

0.0 %

From 52w low

+329.4 %

Market sentiment

Sentiment has improved sharply after a clear revenue/EPS beat, continued patient growth, and a third consecutive profitable quarter; however, discussion still highlights the patent litigation as the main uncertainty.

Why BUY?

Operational performance (rapid sequential sales growth, profitability, and rising cash) reduces financing risk and strengthens the bull case. A material binary risk remains from the patent litigation, supporting a measured add rather than an aggressive increase.

Consider adding in tranches (e.g., 1/3–1/2 of the intended add now and the remainder after legal/commercial updates), with a defined risk budget due to injunction risk.

We're already tracking Liquidia Corporation — here are the latest events we've registered

Recent News

Since 2026-05-14, there have been no new company press releases or FDA/clinical milestone announcements. On May 15, filings showed CEO Roger Jeffs sold 75,000 shares (May 13–15) under a pre-arranged Rule 10b5-1 plan (~$4.3M, price range $53.99–$59.64). On May 19, management presented at the H.C. Wainwright 4th Annual Bioconnect, and new 13F filings indicated multiple institutions increased positions (including GSA Capital Partners). The stock continued higher and printed a new 52-week high around May 19 (close ~ $59.98). The United Therapeutics patent dispute over YUTREPIA remains the key risk.

Dilution Risk

Assessment: Low

Create free account — follow 3 companies

What Firelda Watch includes for Liquidia Corporation

Add the company to your watchlist and get all of this automatically.

Free: 3 companies on your watchlist
Change history and monitoring for every company you follow
Sunday weekly brief — AI roundup of the week's news
Watch/Ultra: same-day email when something material happens

Want to see what a finished analysis looks like?

View a sample analysis

This is a real Firelda analysis. Your analysis of Liquidia Corporation will be delivered in the same format.

Own Liquidia Corporation? Create a free account and follow up to 3 companies — change history, weekly brief, and email when the picture changes. Upgrade to Watch for more slots and same-day alerts.

Follow 3 companies free